SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Dwyer who wrote (159)11/11/1997 7:54:00 PM
From: NeuroInvestment  Read Replies (1) of 496
 
The differences are:
1) NAALADase is an enzyme which operates presynaptically, cleaving glutamate from aspartate during ischemic stress, causing the glutamate overrelease that leads to excitotoxicity. To inhibit NAALADase is thus to intervene upstream in blocking glutamate overrelease, hopefully avoiding the pitfalls that have beset postsynaptic tactics.

2) PARP is an enzyme which operates far downstream in the ischemic cascade; it is overproduced during excitotoxicity and undermines the neuron's ability to maintain anaerobic metabolism. The notion is that by maintaining the ATP energy system, the neuron can pump out excess calcium (which had been allowed in by the glutametergic overrelease which opened ion channels).

It is the presynaptic strategy that has the most promise, because once you move far downstream, there are many biochemical anomalies that have to be remediated (lactic acidosis, free radical oxidants, etc): better to 'nip them in the bud.' NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News